{"result": "(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a leading organization that provides standards of medical care in diabetes and conducts research to improve diabetes care and education.)\n##\n(\"entity\"<|>GÓMEZ-HUELGAS R<|>PERSON<|>Gómez-Huelgas R is an author involved in the consensus document on the treatment of type 2 diabetes in patients with chronic kidney disease.)\n##\n(\"entity\"<|>MARTÍNEZ-CASTELAO A<|>PERSON<|>Martínez-Castelao A is an author involved in the consensus document on the treatment of type 2 diabetes in patients with chronic kidney disease.)\n##\n(\"entity\"<|>ARTOLA S<|>PERSON<|>Artola S is an author involved in the consensus document on the treatment of type 2 diabetes in patients with chronic kidney disease.)\n##\n(\"entity\"<|>GÓRRIZ JL<|>PERSON<|>Górriz JL is an author involved in the consensus document on the treatment of type 2 diabetes in patients with chronic kidney disease.)\n##\n(\"entity\"<|>MENÉNDEZ E<|>PERSON<|>Menéndez E is an author involved in the consensus document on the treatment of type 2 diabetes in patients with chronic kidney disease.)\n##\n(\"entity\"<|>BRUTTOMESSO D<|>PERSON<|>Bruttomesso D is an author of a study comparing continuous subcutaneous insulin infusion and multiple daily injections in type 1 diabetes.)\n##\n(\"entity\"<|>CRAZZOLARA D<|>PERSON<|>Crazzolara D is an author of a study comparing continuous subcutaneous insulin infusion and multiple daily injections in type 1 diabetes.)\n##\n(\"entity\"<|>MARAN A<|>PERSON<|>Maran A is an author of a study comparing continuous subcutaneous insulin infusion and multiple daily injections in type 1 diabetes.)\n##\n(\"entity\"<|>COSTA S<|>PERSON<|>Costa S is an author of a study comparing continuous subcutaneous insulin infusion and multiple daily injections in type 1 diabetes.)\n##\n(\"entity\"<|>DAL POS M<|>PERSON<|>Dal Pos M is an author of a study comparing continuous subcutaneous insulin infusion and multiple daily injections in type 1 diabetes.)\n##\n(\"entity\"<|>GIRELLI A<|>PERSON<|>Girelli A is an author of a study comparing continuous subcutaneous insulin infusion and multiple daily injections in type 1 diabetes.)\n##\n(\"entity\"<|>DIABETES TYPE 1<|>EVENT<|>Diabetes Type 1 is a chronic condition that requires careful management of insulin levels and blood glucose.)\n##\n(\"entity\"<|>DIABETES TYPE 2<|>EVENT<|>Diabetes Type 2 is a chronic condition that affects the way the body processes blood sugar (glucose) and may require medication management.)\n##\n(\"relationship\"<|>GÓMEZ-HUELGAS R<|>AMERICAN DIABETES ASSOCIATION<|>Gómez-Huelgas R contributed to the consensus document published by the American Diabetes Association regarding diabetes treatment<|>7)\n##\n(\"relationship\"<|>MARTÍNEZ-CASTELAO A<|>AMERICAN DIABETES ASSOCIATION<|>Martínez-Castelao A contributed to the consensus document published by the American Diabetes Association regarding diabetes treatment<|>7)\n##\n(\"relationship\"<|>ARTOLA S<|>AMERICAN DIABETES ASSOCIATION<|>Artola S contributed to the consensus document published by the American Diabetes Association regarding diabetes treatment<|>7)\n##\n(\"relationship\"<|>GÓRRIZ JL<|>AMERICAN DIABETES ASSOCIATION<|>Górriz JL contributed to the consensus document published by the American Diabetes Association regarding diabetes treatment<|>7)\n##\n(\"relationship\"<|>MENÉNDEZ E<|>AMERICAN DIABETES ASSOCIATION<|>Menéndez E contributed to the consensus document published by the American Diabetes Association regarding diabetes treatment<|>7)\n##\n(\"relationship\"<|>BRUTTOMESSO D<|>DIABETES TYPE 1<|>Bruttomesso D conducted a study related to the management of Diabetes Type 1<|>8)\n##\n(\"relationship\"<|>CRAZZOLARA D<|>DIABETES TYPE 1<|>Crazzolara D conducted a study related to the management of Diabetes Type 1<|>8)\n##\n(\"relationship\"<|>MARAN A<|>DIABETES TYPE 1<|>Maran A conducted a study related to the management of Diabetes Type 1<|>8)\n##\n(\"relationship\"<|>COSTA S<|>DIABETES TYPE 1<|>Costa S conducted a study related to the management of Diabetes Type 1<|>8)\n##\n(\"relationship\"<|>DAL POS M<|>DIABETES TYPE 1<|>Dal Pos M conducted a study related to the management of Diabetes Type 1<|>8)\n##\n(\"relationship\"<|>GIRELLI A<|>DIABETES TYPE 1<|>Girelli A conducted a study related to the management of Diabetes Type 1<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: os beneficios de la terapia con ISCI parecen ser dependientes de la HbA1c (a mayor HbA1c, mayor beneficio) |\n| Menor riesgo de hipoglucemia grave | Parece disminuir hasta 4,2 veces. Mayores beneficios aparecen en aquellos pacientes con DM1 con peor control metabólico y más riesgo de hipoglucemias graves |\n| Menor incidencia de hipoglucemias no graves | Hipoglucemias de menor gravedad disminuyen hasta un 75% con ISCI frente a las DMI |\n| Menor variabilidad glucémica | |\n| Adaptabilidad del ritmo basal y de los bolos de insulina según las necesidades | |\n| Empleo de la misma zona de punción para la administración de la insulina, con lo que se reduce la variabilidad en la absorción | |\n| Menor riesgo de hipoglucemias nocturnas y de hiperglucemias de ayuno (fenómeno del alba) | |\n| Mejoría de la calidad de vida percibida | |\n\nde las necesidades de insulina también puede hacer necesario un descenso de la dosis de ciertas terapias antidiabéticas hipoglucemiantes como repaglinida y las sulfonilureas.\n\nReferencias:\n- American Diabetes Association. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes- 2019. Diabetes Care. 2019;42(Suppl. 1):S173-81.\n- Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E; en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Med Clin (Barc). 2014;142(2):85.e1-10.\n\nReferencias:\n- Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, et al. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med. 2008;25(3):326-32.\n- Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019 Apr 3. [Epub ahead of print].\n- Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765-74.\n\n## 70. ¿Cuál de las siguientes situaciones no es causa de un aumento de los requerimientos de insulina en un paciente diabético?\n\nA. Infección urinaria.\nB. Encamamiento por fractura.\nC. Insuficiencia renal.\nD. Todas.\n\n### COMENTARIO\n\nLas enfermedades concomitantes (infecciones, cirugía, hospitalización) aumentan las necesidades de insulina en los sujetos con diabetes, tanto por el estrés propio de la situación como por la situación de reposo.\n\nSin embargo, en la insuficiencia renal, el aclaramiento de la insulina disminuye, lo que reduce las necesidades de insulina e incrementa el riesgo de hipoglucemia. Este descenso\n\n## 71. Respecto a la introducción de fármacos tras el parto en mujeres con DM2 e hipertensión arterial, señale la respuesta incorrecta:\n\nA. Los IECA son compatibles con la lactancia.\nB. Los ARA-II son compatibles con la lactancia.\nC. La repaglinida es compatible con la lactancia.\nD. La glibenclamida es compatible con la lactancia.\n\n### COMENTARIO\n\nEn vista de los beneficios nutricionales e inmunológicos inmediatos de la lactancia materna para el bebé, todas las mujeres, incluidas las que tienen diabetes, deben recibir apoyo en sus intentos de amamantar. La lactancia materna también puede conferir beneficios metabólicos a largo plazo tanto para la madre como para la descendencia.\n\nEl enalapril (IECA) se excreta en la leche materna en cantidad clínicamente no significativa y no se han observado problemas en lactantes cuyas madres la tomaban, ni problemas en el establecimiento de la lactancia. Es una medicación de uso autorizado en lactantes pequeños y, fuera de ficha técnica, en neonatos.\n\nLos ARA-II, al menos candesartán, eprosartán, valsartán, losartán y olmesartán tienen riesgo bajo probable, es decir son bastante seguros.\n\nLa repaglinida presenta riesgo potencial de hipoglucemia y se han observado efectos adversos en animales lactantes. Se clasifica, por tanto, como\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}